Innovation Pharmaceuticals Inc. (IPIX)
OTCMKTS: IPIX · Delayed Price · USD
0.0177
+0.0077 (77.00%)
Apr 18, 2024, 11:18 AM EDT - Market open
Company Description
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective.
Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19.
The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017.
Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Innovation Pharmaceuticals Inc.
| Country | MA |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Leo Ehrlich CPA |
Contact Details
Address: 301 Edgewater Place, Suite 100 Wakefield, Massachusetts 01880 United States | |
| Phone | 978-921-4125 |
| Website | ipharminc.com |
Stock Details
| Ticker Symbol | IPIX |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001355250 |
| CUSIP Number | 45782D100 |
| ISIN Number | US45782D1000 |
| Employer ID | 30-0565645 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leo Ehrlich CPA | Chairman, Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and Secretary |
| Jane Harness M.S., MP | Senior Vice President of Clinical Sciences and Portfolio Management |
| Jim Boeheim | Business Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 1, 2024 | 8-K | Current Report |
| Dec 5, 2023 | 8-K | Current Report |
| Nov 20, 2023 | 10-Q | Quarterly Report |
| Nov 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Oct 30, 2023 | 8-K | Current Report |
| Sep 28, 2023 | 10-K | Annual Report |
| May 15, 2023 | 10-Q | Quarterly Report |
| Feb 15, 2023 | 10-Q | Quarterly Report |
| Feb 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Jan 4, 2023 | 8-K | Current Report |